LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

Начало・Списък с акции・Schrodinger Inc

Schrodinger Inc

Отворен

СекторЗдравеопазване

11.67 -0.09

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.23

Максимум

11.73

Ключови измерители
By Trading Economics
Приходи	169M 136M
Продажби	33M 87M
EPS	-0.18
Марж на печалбата	155.644
Служители	850
EBITDA	67M 36M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+67.68% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	50M 876M
Предишно отваряне	11.76
Предишно затваряне	11.67

Настроения в новините

By Acuity

100%

330 / 350 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

23.27 / 26.13 Подкрепа & съпротива

Schrodinger Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.03.2026 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Infosys Agrees to Acquire Stratus

25.03.2026 г., 23:58 ч. UTC

Печалби

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25.03.2026 г., 23:58 ч. UTC

Печалби

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25.03.2026 г., 23:57 ч. UTC

Печалби

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25.03.2026 г., 23:57 ч. UTC

Печалби

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25.03.2026 г., 23:56 ч. UTC

Печалби

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25.03.2026 г., 23:56 ч. UTC

Печалби

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25.03.2026 г., 23:41 ч. UTC

Печалби

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25.03.2026 г., 23:34 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Declines on Possible Technical Correction -- Market Talk

25.03.2026 г., 22:08 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.03.2026 г., 22:08 ч. UTC

Пазарно говорене

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25.03.2026 г., 22:07 ч. UTC

Печалби

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25.03.2026 г., 22:07 ч. UTC

Печалби

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25.03.2026 г., 22:07 ч. UTC

Печалби

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25.03.2026 г., 22:07 ч. UTC

Печалби

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25.03.2026 г., 22:07 ч. UTC

Печалби

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25.03.2026 г., 21:58 ч. UTC

Пазарно говорене

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25.03.2026 г., 21:37 ч. UTC

Пазарно говорене

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25.03.2026 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25.03.2026 г., 21:13 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25.03.2026 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

25.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

25.03.2026 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25.03.2026 г., 20:31 ч. UTC

Печалби

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25.03.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25.03.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25.03.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25.03.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Schrodinger Inc Прогноза

Ценова цел

By TipRanks

67.68% нагоре

12-месечна прогноза

Среден 19.4 USD 67.68%

Висок 25 USD

Нисък 13 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Schrodinger Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Schrodinger Inc през последните 3 месеца.

Техническа оценка

By Trading Central

23.27 / 26.13Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

330 / 350 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.